ES2321725T3 - Utilizacion de inhibidores de glucosidasa para un tratamiento de la mucoviscidosis. - Google Patents

Utilizacion de inhibidores de glucosidasa para un tratamiento de la mucoviscidosis. Download PDF

Info

Publication number
ES2321725T3
ES2321725T3 ES04805405T ES04805405T ES2321725T3 ES 2321725 T3 ES2321725 T3 ES 2321725T3 ES 04805405 T ES04805405 T ES 04805405T ES 04805405 T ES04805405 T ES 04805405T ES 2321725 T3 ES2321725 T3 ES 2321725T3
Authority
ES
Spain
Prior art keywords
dnj
cells
cftr
treatment
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES04805405T
Other languages
English (en)
Spanish (es)
Inventor
Frederic Becq
Caroline Norez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Universite de Poitiers
Original Assignee
Centre National de la Recherche Scientifique CNRS
Universite de Poitiers
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Universite de Poitiers filed Critical Centre National de la Recherche Scientifique CNRS
Application granted granted Critical
Publication of ES2321725T3 publication Critical patent/ES2321725T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Steroid Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
ES04805405T 2003-11-07 2004-11-05 Utilizacion de inhibidores de glucosidasa para un tratamiento de la mucoviscidosis. Expired - Lifetime ES2321725T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0313134A FR2861991B1 (fr) 2003-11-07 2003-11-07 Utilisation d'inhibiteurs de glucosidase pour une therapie de la mucoviscidose
FR0313134 2003-11-07

Publications (1)

Publication Number Publication Date
ES2321725T3 true ES2321725T3 (es) 2009-06-10

Family

ID=34508347

Family Applications (1)

Application Number Title Priority Date Filing Date
ES04805405T Expired - Lifetime ES2321725T3 (es) 2003-11-07 2004-11-05 Utilizacion de inhibidores de glucosidasa para un tratamiento de la mucoviscidosis.

Country Status (24)

Country Link
US (2) US7973054B2 (https=)
EP (1) EP1680105B1 (https=)
JP (1) JP4740868B2 (https=)
KR (2) KR100979276B1 (https=)
CN (1) CN100534432C (https=)
AT (1) ATE423561T1 (https=)
AU (1) AU2004289083B2 (https=)
BR (1) BRPI0416228A (https=)
CA (1) CA2545133C (https=)
CY (1) CY1110468T1 (https=)
DE (1) DE602004019674D1 (https=)
DK (1) DK1680105T3 (https=)
ES (1) ES2321725T3 (https=)
FR (1) FR2861991B1 (https=)
HR (1) HRP20090159T1 (https=)
IL (1) IL175453A (https=)
NO (1) NO336904B1 (https=)
NZ (1) NZ547261A (https=)
PL (1) PL1680105T3 (https=)
PT (1) PT1680105E (https=)
RU (1) RU2358725C2 (https=)
SI (1) SI1680105T1 (https=)
WO (1) WO2005046672A2 (https=)
ZA (1) ZA200603726B (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2932982B1 (en) 2005-05-17 2018-10-03 Amicus Therapeutics, Inc. A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives
AU2007241622A1 (en) * 2006-04-24 2007-11-01 Academisch Medisch Centrum Improved treatment of cystic fibrosis
ES2573498T3 (es) 2006-05-16 2016-06-08 Amicus Therapeutics, Inc. Opciones de tratamiento para la enfermedad de Fabry
EP2352828B1 (en) * 2008-09-11 2015-02-25 Galapagos N.V. Method for identifying compounds useful for increasing the functional activity and cell surface expression of cf-associated mutant cystic fibrosis transmembrane conductance regulator
ITFE20080032A1 (it) * 2008-10-23 2010-04-24 Azienda Ospedaliera Istituti Ospit Alieri Di Vero Effetto anti infiammatorio del miglustat cellule dell'epitelio bronchiale
GB201000499D0 (en) 2010-01-13 2010-03-03 Fleet George W J Treatment of cystic fibrosis
WO2011095772A2 (en) 2010-02-04 2011-08-11 Summit Corporation Plc Novel iminosugar therapeutics
GB201006434D0 (en) 2010-04-19 2010-06-02 Summit Corp Plc Novel iminosugar combinations
KR20200032244A (ko) 2012-03-07 2020-03-25 아미쿠스 세라퓨틱스, 인코포레이티드 폼페병의 치료를 위한 고농도 알파-글루코시다제 조성물
KR20160055916A (ko) * 2013-09-16 2016-05-18 이머전트 바이롤로지 엘엘씨 데옥시노지리마이신 유도체 및 그의 이용 방법
FR3017536B1 (fr) 2014-02-18 2017-05-26 Univ La Rochelle Compositions pour la prevention et/ou le traitement de pathologies liees a l'alpha-glucosidase
WO2016054231A1 (en) 2014-09-30 2016-04-07 Amicus Therapeutics, Inc. Highly potent acid alpha-glucosidase with enhanced carbohydrates
KR102510941B1 (ko) 2015-12-30 2023-03-20 아미쿠스 세라퓨틱스, 인코포레이티드 폼페병 치료용의 강화된 산 알파-글루코시다제
US10227577B2 (en) 2016-03-30 2019-03-12 Amicus Therapeutics, Inc. Method for selection of high M6P recombinant proteins
IL325155A (en) 2016-03-30 2026-02-01 Amicus Therapeutics Inc Formulations containing recombinant acid alpha-glucosidase
EP3448410A1 (en) * 2016-04-29 2019-03-06 Institut Pasteur Methods and compositions for modifying cystic fibrosis transmembrane conductance regulator activity
US10478427B2 (en) * 2016-07-07 2019-11-19 National University Corporation Chiba University Therapeutic agent for fibrosis and inhibitor of nuclear translocation of phosphorylated smad
EP3624831B1 (en) 2017-05-15 2023-03-29 Amicus Therapeutics, Inc. Recombinant human acid alpha-glucosidase
AU2018278247B2 (en) * 2017-06-01 2022-07-28 Idorsia Pharmaceuticals Ltd Crystalline form of N-butyldeoxygalactonojirimycin
CN108187051A (zh) * 2018-01-30 2018-06-22 中国药科大学 α-L-岩藻糖苷酶及抑制剂用于制备防治心肌缺血损伤的药物的用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO154918C (no) * 1977-08-27 1987-01-14 Bayer Ag Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
TW275621B (https=) * 1992-10-27 1996-05-11 Merck & Co Inc
WO1998020123A2 (en) * 1996-11-04 1998-05-14 Institut Curie Stable cell lines expressing the cftr protein or a mutant of this protein, tool for selecting molecules having an effect on the intracellular transport of these proteins
ID21411A (id) * 1997-12-10 1999-06-10 Takeda Chemical Industries Ltd Agen untuk mengobati daya tahan glukosa yang berisiko tinggi rusak
US6274597B1 (en) * 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
AU5799500A (en) * 1999-06-29 2001-01-22 Mcgill University Human alpha 1,2-mannosidase
US6476194B1 (en) * 1999-06-29 2002-11-05 National Research Council Of Canada Method for folding unfolded proteins
AU7398900A (en) * 1999-09-23 2001-04-24 Hospital For Sick Children, The Three-dimensional structure and crystal of a class i alpha1,2-mannosidase, and methods of use thereof
US20050053625A1 (en) * 2001-10-30 2005-03-10 Block Timothy M Method of treating viral infections
US7081260B2 (en) * 2002-10-29 2006-07-25 Council Of Scientific And Industrial Research α-Glucosidase inhibitors from a natural source
PT2441467E (pt) 2003-01-31 2015-10-12 Sinai School Medicine Terapia combinada para o tratamento de transtornos associados a uma deficiência proteica
US7071341B2 (en) * 2003-02-28 2006-07-04 Council Of Scientific And Industrial Research α-Glucosidase inhibitors and their synthesis from a natural source

Also Published As

Publication number Publication date
CA2545133A1 (fr) 2005-05-26
AU2004289083B2 (en) 2009-12-03
FR2861991A1 (fr) 2005-05-13
PL1680105T3 (pl) 2009-07-31
PT1680105E (pt) 2009-05-20
NO336904B1 (no) 2015-11-23
ZA200603726B (en) 2007-12-27
DK1680105T3 (da) 2009-06-29
KR20060130058A (ko) 2006-12-18
FR2861991B1 (fr) 2008-01-18
NO20062617L (no) 2006-07-25
EP1680105A2 (fr) 2006-07-19
KR20100038452A (ko) 2010-04-14
IL175453A (en) 2012-09-24
KR100979276B1 (ko) 2010-08-31
ATE423561T1 (de) 2009-03-15
US8242136B2 (en) 2012-08-14
SI1680105T1 (sl) 2009-08-31
DE602004019674D1 (de) 2009-04-09
WO2005046672A2 (fr) 2005-05-26
CA2545133C (fr) 2013-04-16
CY1110468T1 (el) 2015-04-29
IL175453A0 (en) 2008-03-20
US20070213357A1 (en) 2007-09-13
CN1897933A (zh) 2007-01-17
RU2006119914A (ru) 2007-12-20
NZ547261A (en) 2009-11-27
EP1680105B1 (fr) 2009-02-25
HRP20090159T1 (en) 2009-05-31
JP4740868B2 (ja) 2011-08-03
JP2007510699A (ja) 2007-04-26
AU2004289083A1 (en) 2005-05-26
US20110269795A1 (en) 2011-11-03
US7973054B2 (en) 2011-07-05
RU2358725C2 (ru) 2009-06-20
WO2005046672A3 (fr) 2005-09-15
BRPI0416228A (pt) 2007-01-02
CN100534432C (zh) 2009-09-02

Similar Documents

Publication Publication Date Title
ES2321725T3 (es) Utilizacion de inhibidores de glucosidasa para un tratamiento de la mucoviscidosis.
US20090048260A1 (en) Use of pyrrolopyrazine derivatives for the production of medicaments for the treatment of mucoviscidosis and diseases related to protein addressing errors in cells
ES2614931T3 (es) Inhibidores de la piruvato cinasa y métodos de tratamiento de enfermedad
ES2532779T3 (es) Utilización de derivados de purinas para la fabricación de medicamentos para el tratamiento de la mucoviscidosis y de enfermedades relacionadas con un defecto de direccionamiento de las proteínas en las células
Seixas et al. Rab and Arf proteins in genetic diseases
ES2733929T3 (es) Una combinación farmacéutica para el tratamiento del melanoma
KR20200126430A (ko) 특정 ｖｍａｔ2 억제제의 투여 방법
ES3004516T3 (en) Methods of treating sjögren's syndrome using a bruton's tyrosine kinase inhibitor
Poce et al. MmpL3 inhibitors: diverse chemical scaffolds inhibit the same target
Rowland et al. Putative tumor suppressor cytoglobin promotes aryl hydrocarbon receptor ligand–mediated triple negative breast cancer cell death
ITMI980086A1 (it) Composti pirimidin 3-ossido per il trattamento delle patologie muscolo-scheletriche in particolare per il trattamento della
WO2022087176A1 (en) Administration of antipurinergic compositions for treating nervous system disorders
ES2378829T3 (es) Uso de derivados de paulonas para la fabricación de medicamentos para el tratamiento de la mucoviscidosis y de enfermedades ligadas a un defecto de direccionamiento de las proteínas en las células
US20090306430A1 (en) Use of Guanabenz and Its Derivatives for Making Drugs for Treating Cystic Fibrosis and Diseases Related to a Protein Addressing Deficiency in the Cells
Gao et al. Sevoflurane but not propofol provided dual effects of cell survival in human neuroblastoma SH-SY5Y cells
MXPA06005086A (en) Use of glucosidase inhibitors for therapy of mucovisidosis
ES3036880T3 (en) Combinations of masupirdine with donepezil or memantine for treating behavioral and psychological symptoms in patients with dementia
US20070191493A1 (en) Use of n-alkanols as activators of the cftr channel
ES2396360T3 (es) Composición micronizada de un derivado de fenol 2,4-di sustituido
ROLAND et al. Relative Abuse Liability of Triazolam: Experimental Assessment in Animals and Humans
Eigel The regulation and function of the cardiac sodium-calcium exchanger is responsible for calcium dyshomeostasis during anoxia/reoxygenation in guinea-pig ventricular myocytes
HK40007956A (en) Combination of a bcl-2 inhibitor and a mcl-1 inhibitor, uses and pharmaceutical compositions thereof
ES2546897A2 (es) Uso de la metformina y derivados con actividad como inductores de la fosforilación de AMPK para el tratamiento de la fibromialgia